| Titre | | nb de chargement | |
|---|
| Transgene and BioInvent announce clinical trial collaboration and supply agreement with MSD to evaluate BT-001 in combination with KEYTRUDA® | | 129 | |
| Transgene et BioInvent annoncent la conclusion d'un accord avec MSD de collaboration clinique et d'approvisionnement pour évaluer BT-001 en combinaison avec KEYTRUDA® | | 159 | |
| Transgene and BioInvent announce positive progress for BT-001 | | 655 | |
| Transgene et BioInvent présentent les avancées positives de BT-001 | | 1956 | |
| TG4050 | | 5931 | |
| TG4050 | | 5931 | |
| annonce TG4050en | | 5931 | |
| annonce TG4050 | | 5931 | |
| Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022 | | 6311 | |
| Transgene a présenté de nouvelles données de Phase I de TG4050 au congrès de l'ASCO 2022 | | 6593 | |
| Conférence Portzamparc - Paris - 29 juin 2022 | | 7253 | |
| Portzamparc Conference - Paris - June 29, 2022 | | 7253 | |
| Spring European MidCap Event - Paris - 23 & 24 juin 2022 | | 7253 | |
| Spring European MidCap Event - Paris - June 23 & 24, 2022 | | 7253 | |
| UBS Global Healthcare Conference - New York | | 7253 | |
| UBS Global Healthcare Conference - New York | | 7253 | |
| Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and heck carcinoma (HNSCC) | | 7255 | |
| Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and heck carcinoma (HNSCC) | | 7255 | |
| Laurence Espinasse | | 7255 | |
| Laurence Espinasse? | | 7255 | |
| Prof. Jean-Yves Blay? | | 7255 | |
| Pr Jean-Yves Blay | | 7255 | |
| Dr. Alessandro Riva | | 7255 | |
| Dr. Alessandro Riva? | | 7255 | |
| Transgene présentera de nouvelles données préliminaires des essais cliniques de Phase I de TG4050 (plateforme myvac®) au congrès de l'ASCO 2022 | | 11864 | |
| Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022 | | 7907 | |
| Transgene's Combined General Meeting of May 25, 2022 | | 7866 | |
| Assemblée Générale Mixte de Transgene du 25 mai 2022 | | 7778 | |
| Transgene Announces Upcoming Investor Meetings | | 8850 | |
| Transgene annonce ses prochaines rencontres avec les investisseurs | | 8834 | |
| All of Transgene's preclinical and clinical assets progressed in line with expectations in Q1 2022 | | 8911 | |
| Progression de tous les produits précliniques et cliniques de Transgene au premier trimestre 2022 | | 9848 | |
| Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination | | 8463 | |
| Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination | | 8463 | |
| Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients | | 8485 | |
| Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients | | 8485 | |
| Transgene to Present New Positive Preliminary Phase I Clinical Data at AACR 2022, Reinforcing the Potential of TG4050 | | 13262 | |
| Transgene présente de nouvelles données préliminaires de Phase I confirmant le potentiel de TG4050 au congrès de l'AACR 2022 | | 11614 | |
| Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients | | 10816 | |
| Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF | | 10816 | |
| Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF | | 10816 | |
| Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients | | 10816 | |
| Availability of Transgene's 2021 Universal Registration Document | | 12379 | |
| Mise à disposition du document d'enregistrement universel 2021 de Transgene | | 11514 | |
| Availability of Preparatory Documents for the Combined General Meeting of May 25, 2022 | | 11623 | |
| Mise à disposition des documents préparatoires à l'Assemblée générale du 25 mai 2022 | | 11377 | |
| Transgene's Board of Directors strengthens its governance and proposes the appointment of Dr. Alessandro Riva as Independent Chairman | | 14020 | |
| Le conseil d'administration de Transgene renforce sa gouvernance et propose la nomination du Dr Alessandro Riva en qualité de Président Indépendant | | 11403 | |
| Transgene confirms the potential of its two innovative platforms and expects significant clinical results in 2022 | | 25151 | |
| Transgene confirme le potentiel de ses deux plateformes innovantes et attend des résultats cliniques significatifs en 2022 | | 15703 | |
| Transgene and BioInvent Announce Poster Presentation on BT-001, a Novel Antibody-encoding Oncolytic Virus, at AACR 2022 | | 16423 | |
| Transgene et BioInvent présenteront un poster à l'AACR 2022 sur BT-001, un virus oncolytique innovant | | 12569 | |
| Transgene to Present New Positive Preliminary Phase I Data on TG4050 (myvac® platform), its Individualized Therapeutic Cancer Vaccine, at AACR 2022 | | 14315 | |
| Transgene présentera des nouvelles données préliminaires positives des Phases I avec TG4050 à l'AACR 2022 | | 12785 | |
| BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment | | 11982 | |
| BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment | | 11982 | |
| Vectorized Treg-depleting ?CTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject "cold" tumors | | 11982 | |
| Vectorized Treg-depleting ?CTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject "cold" tumors | | 11982 | |
| Éthique et conformité | | 11982 | |
| Corporate governance | | 11982 | |
| Ethics & compliance | | 11982 | |
| Transgene appoints Steven Bloom as Chief Business Officer | | 22299 | |
| Transgene annonce la nomination de Steven Bloom au poste de Directeur du Business Development | | 12571 | |
| Ethics and compliance | | 11982 | |
| Éthique & conformité | | 11982 | |
| Custom Styles | | 11984 | |
| Transgene and BioInvent joint JITC publication demonstrates the potential of BT-001 oncolytic virus to provide therapeutic benefit beyond current anti-PD1/ anti-CTLA-4 immune checkpoint blockade | | 14538 | |
| Transgene et BioInvent publient dans le JITC des données de preuve de concept préclinique du virus oncolytique BT-001 | | 14220 | |
| | 11988 | |
| Transgene and PersonGen Announce Collaboration to Evaluate a New Combination Therapy Against Solid Tumors | | 22642 | |
| Transgene et PersonGen annoncent une collaboration pour l'évaluation d'une nouvelle combinaison thérapeutique contre les tumeurs solides | | 19212 | |
| Transgene announces Financial Calendar for 2022 | | 12792 | |
| Transgene présente son calendrier de communication financière pour 2022 | | 13165 | |
| Biomed Event - Paris | | 15200 | |
| Biomed Event - Paris | | 15200 | |
| Biotech Showcase Investor Conference Digital- January 17 to 19, 2022 | | 15200 | |
| Biotech Showcase Investor Conference Virtuel - 17 au 19 janvier 2022 | | 15200 | |
| Biotech Showcase Investor Conference, in conjunction with the J.P. Morgan Healthcare conference - Digital - January 10 to 12, 2022 | | 15200 | |
| Biotech Showcase Investor Conference, en parallèle de la conférence annuelle J. P. Morgan - Virtu - 10 au 12 janvier 2022 | | 15200 | |
| 25th ODDO BHF Digital Forum - Digital - January 6, 7, 10 and 11, 2022 | | 15200 | |
| 11ème édition du LifeSci Advisors Corporate Access Event - Virtuel - 5 au 7 janvier 2022 | | 15200 | |
| 11th Annual LifeSci Advisors Corporate Access Event - Digital - January 5 to 7, 2022 | | 15200 | |
| ODDO BHF Digital Forum - Virtuel - 6, 7, 10 et 11 janvier 2022 | | 15200 | |
| Transgene announces investor Meeting for January 2022 | | 16168 | |
| Transgene annonce ses rencontres avec les investisseurs en janvier 2022 | | 17308 | |
| License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Invir.IO Platform | | 15200 | |
| Levée dOption de Licence par AstraZeneca pour un Virus Oncolytique issu de la Plateforme Invir.IO | | 15200 | |
| Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgenes Invir.IO Platform | | 41388 | |
| Transgene annonce une levée doption de licence par AstraZeneca pour un virus oncolytique issu de sa plateforme Invir.IO | | 18757 | |
| TG4050, First positive clinical data from Phase I clinical trials | | 15200 | |
| TG4050, Premiers résultats positifs des essais de Phase I (en français) | | 15200 | |
| Transgene and NEC announce positive preliminary data from Phase I studies of TG4050, a novel individualized neoantigen cancer vaccine | | 31367 | |
| Transgene et NEC annoncent des premiers résultats positifs des essais de Phase I de TG4050, un vaccin thérapeutique individualisé innovant contre le cancer | | 17565 | |
| annonceHome | | 15200 | |
| annonceHomeUS | | 15200 | |
| Icon | | 15200 | |
| TG4050 | | 15200 | |
| annonce substitut | | 15200 | |
| annonce | | 15200 | |
| Careers | | 15200 | |
| Annual General Meeting | | 15200 | |
| événements et presentations | | 15200 | |
| Analysts | | 15200 | |
| General | | 15200 | |
| Key figures | | 15200 | |
| Financial reports | | 15200 | |
| Information boursière | | 15200 | |
| Financial information | | 15200 | |
| Regulated information | | 15200 | |
| Publications | | 15200 | |
| RH(en) | | 15200 | |
| Icon | | 15200 | |
| Transgene and BioInvent to present preclinical data on BT-001 oncolytic virus at SITC 2021 | | 15661 | |
| Transgene reports business update and Q3 2021 financial position | | 15200 | |
| Transgene and BioInvent present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021 | | 15428 | |
| Transgene et BioInvent présentent des données précliniques soulignant la forte activité antitumorale du virus oncolytique BT-001 au SITC 2021 | | 15865 | |
| Transgene publie sa situation financière et fait un point sur son activité au troisième trimestre 2021 | | 15838 | |
| Transgene et BioInvent présenteront des données précliniques sur le virus oncolytique BT-001 au SITC 2021 | | 15448 | |
| annonce substitut | | 15200 | |
| annonce | | 15200 | |
| annonce | | 15200 | |
| Nous rejoindre | | 15200 | |
| esmo | | 15200 | |
| esmo2021 | | 15200 | |
| bg3 | | 15200 | |
| bg2 | | 15200 | |
| bg1 | | 15200 | |
| Statistiques | | 15200 | |
| RH | | 15200 | |
| produits : BT-001 | | 15200 | |
| produits : TG6002 | | 15200 | |
| produits : TG4001 | | 15200 | |
| produits : TG4050 | | 15200 | |
| Publications | | 15200 | |
| techno invirio | | 15200 | |
| techno myvac | | 15200 | |
| techno Oncolytic viruses | | 15200 | |
| techno Therapeutic Vaccines | | 15200 | |
| FAQ | | 15200 | |
| | 15200 | |
| produits : 5 OVs teaser | | 15200 | |
| produits : OVs teaser | | 15200 | |
| produits : BT-001 teaser | | 15200 | |
| produits : TG6002 teaser | | 15200 | |
| produits : TG4001 teaser | | 15200 | |
| produits : TG4050 teaser | | 15200 | |
| pipeline | | 15200 | |
| CORPORATE GOVERNANCE | | 15200 | |
| Dr. Laurence ZITVOGEL | | 15200 | |
| Sandrine Flory TSGH | | 15200 | |
